QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PYPL   73.30 (-0.79%)
PFE   40.22 (-0.42%)
NFLX   327.66 (-0.22%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PYPL   73.30 (-0.79%)
PFE   40.22 (-0.42%)
NFLX   327.66 (-0.22%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PYPL   73.30 (-0.79%)
PFE   40.22 (-0.42%)
NFLX   327.66 (-0.22%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PYPL   73.30 (-0.79%)
PFE   40.22 (-0.42%)
NFLX   327.66 (-0.22%)
OTCMKTS:KHTRF

Knight Therapeutics - KHTRF News Today

$3.47
-0.11 (-2.98%)
(As of 03/24/2023 08:52 PM ET)
Add
Compare
Today's Range
$3.47
▼
$3.47
50-Day Range
$3.47
▼
$3.96
52-Week Range
$3.47
▼
$4.77
Volume
100 shs
Average Volume
2,388 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.08
Get Knight Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KHTRF and its competitors with MarketBeat's FREE daily newsletter.


KHTRF Media Mentions By Week

KHTRF Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

KHTRF
News Sentiment
▼
0.00

0.67
▲
Average
Medical
News Sentiment

KHTRF News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

KHTRF Articles
This Week
▼
4

0
▲
KHTRF Articles
Average Week

SourceHeadline
markets.businessinsider.com logoBloom Burton Keeps Their Buy Rating on Knight Therapeutics (KHTRF)
markets.businessinsider.com - March 26 at 9:58 AM
markets.businessinsider.com logoRBC Capital Sticks to Their Buy Rating for Knight Therapeutics (KHTRF)
markets.businessinsider.com - March 24 at 7:41 PM
finance.yahoo.com logoG2S2 CAPITAL INC. ANNOUNCES INVESTMENT IN KNIGHT THERAPEUTICS INC.
finance.yahoo.com - March 24 at 12:00 AM
markets.businessinsider.com logoStifel Nicolaus Remains a Hold on Knight Therapeutics (KHTRF)
markets.businessinsider.com - March 23 at 6:59 PM
finance.yahoo.com logoBerkadia Forges Alliance With Knight Frank
finance.yahoo.com - January 26 at 3:35 PM
marketwatch.com logoKnight Therapeutics Closes $38.5 Mln Loan With International Finance Corp.
marketwatch.com - December 23 at 12:40 PM
finance.yahoo.com logoKnight Therapeutics Closes US$38.5 million Loan with IFC
finance.yahoo.com - December 23 at 7:39 AM
seekingalpha.com logoKnight Therapeutics Inc. (KHTRF) Q3 2022 Earnings Call Transcript
seekingalpha.com - November 13 at 3:41 PM
finance.yahoo.com logoKnight Therapeutics Third Quarter 2022 Earnings: Beats Expectations
finance.yahoo.com - November 12 at 11:28 AM
finance.yahoo.com logoKnight to Present at Stifel Healthcare Conference
finance.yahoo.com - November 9 at 7:46 PM
finance.yahoo.com logoNotice of Knight Therapeutics' Third Quarter 2022 Results Conference Call
finance.yahoo.com - November 3 at 12:08 PM
seekingalpha.com logoKnight Therapeutics' (KHTRF) CEO Samira Sakhia on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com - August 12 at 4:24 PM
benzinga.com logoG2S2 CAPITAL INC. FILES EARLY WARNING REPORT FOR INVESTMENT IN KNIGHT THERAPEUTICS INC.
benzinga.com - August 12 at 4:16 AM
nasdaq.com logoKnight Therapeutics To Relaunch AKYNZEO In Brazil
nasdaq.com - July 4 at 4:06 PM
finance.yahoo.com logoDoes Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?
finance.yahoo.com - June 14 at 9:04 AM
seekingalpha.com logoKnight Therapeutics enters license, supply pacts with Rigel
seekingalpha.com - May 24 at 11:11 AM
finance.yahoo.com logoKnight Therapeutics and Helsinn Healthcare SA Enter into Exclusive License, Distribution, and Supply Agreement for Akynzeo® and Aloxi®
finance.yahoo.com - May 12 at 7:24 AM
finance.yahoo.com logoKnight Therapeutics Inc. (TSE:GUD) insiders placed bullish bets worth CA$3.1m in the last 12 months
finance.yahoo.com - March 31 at 1:41 PM
seekingalpha.com logoKnight Therapeutics reports Q4 results
seekingalpha.com - March 25 at 10:22 PM
finance.yahoo.com logoNotice of Knight Therapeutics' Fourth Quarter and Year End 2021 Results Conference Call
finance.yahoo.com - March 17 at 7:38 AM
nasdaq.com logoKnight Therapeutics Inc (KHTRF)
nasdaq.com - January 7 at 8:05 AM
finance.yahoo.com logoIs Knight Therapeutics (TSE:GUD) Using Too Much Debt?
finance.yahoo.com - December 14 at 12:24 PM
finance.yahoo.com logoKnight to Present at Stifel GMP’s The Future of Healthcare Conference
finance.yahoo.com - December 2 at 8:29 PM
finance.yahoo.com logoKnight Therapeutics Reports Third Quarter 2021
finance.yahoo.com - November 11 at 8:07 AM
finance.yahoo.com logoWhat Type Of Shareholders Make Up Knight Therapeutics Inc.'s (TSE:GUD) Share Registry?
finance.yahoo.com - September 30 at 11:02 AM
finance.yahoo.com logoKnight Therapeutics Inc. places No. 27 on The Globe and Mail’s third-annual ranking of Canada’s Top Growing Companies
finance.yahoo.com - September 24 at 1:34 PM
msn.com logoBRIEF-Knight Therapeutics Enters Into Exclusive Supply And Distribution Agreement With Incyte
msn.com - September 23 at 8:22 AM
markets.businessinsider.com logoWhat Wall Street expects from Knight Therapeutics's earnings
markets.businessinsider.com - August 13 at 7:38 AM
finance.yahoo.com logoKnight Therapeutics Reports Second Quarter 2021
finance.yahoo.com - August 13 at 7:38 AM
marketwatch.com logoKnight Therapeutics Gets Health Canada Approval for Neratinib
marketwatch.com - July 8 at 3:03 AM
finance.yahoo.com logoKnight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
finance.yahoo.com - July 7 at 11:57 AM
finance.yahoo.com logoKnight Therapeutics Reports First Quarter 2021 Results
finance.yahoo.com - May 14 at 7:37 AM
finance.yahoo.com logoIIROC Trade Resumption - GUD
finance.yahoo.com - May 13 at 1:25 PM
benzinga.com logoKnight Therapeutics to Acquire Regional Rights to Exelon®
benzinga.com - April 23 at 7:33 AM
finance.yahoo.com logoKnight to Present at the 2021 Bloom Burton & Co. Healthcare Virtual Investor Conference
finance.yahoo.com - April 13 at 6:39 PM
theglobeandmail.com logoKnight Therapeutics stock underperforms, disappoint faithful
theglobeandmail.com - April 1 at 7:57 AM
seekingalpha.com logoKnight Therapeutics Inc. (KHTRF) CEO Jonathan Ross Goodman on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - March 27 at 1:37 AM
markets.businessinsider.com logoHere's what Wall Street expects from Knight Therapeutics's earnings
markets.businessinsider.com - March 25 at 2:32 PM
finance.yahoo.com logoKnight Therapeutics Announces Canadian Commercial Launch of IBSRELA™ - New Innovative Treatment for Irritable Bowel Syndrome with Constipation
finance.yahoo.com - March 1 at 7:15 PM
finance.yahoo.com logoRock star Growth Puts Knight Therapeutics (TSE:GUD) In A Position To Use Debt
finance.yahoo.com - January 6 at 8:43 AM
finance.yahoo.com logoKnight Announces Filing of Preliminary Base Shelf Prospectus
finance.yahoo.com - December 10 at 5:00 PM
finance.yahoo.com logoTime To Worry? Analysts Are Downgrading Their Knight Therapeutics Inc. (TSE:GUD) Outlook
finance.yahoo.com - November 18 at 8:43 AM
finance.yahoo.com logoKnight Therapeutics Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
finance.yahoo.com - November 17 at 12:32 PM
finance.yahoo.com logoEstimating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)
finance.yahoo.com - November 16 at 3:24 PM
finance.yahoo.com logoKnight Therapeutics Reports Third Quarter 2020 Results
finance.yahoo.com - November 13 at 7:40 AM
finance.yahoo.com logoNotice of Knight Therapeutics' Third Quarter 2020 Results Conference Call
finance.yahoo.com - November 6 at 7:36 AM
in.finance.yahoo.com logoKnight Therapeutics Inc. (KHTRF)
in.finance.yahoo.com - October 8 at 2:25 PM
seekingalpha.com logoHealth Canada OK's Knight and TherapeuticsMD for BIJUVA
seekingalpha.com - September 21 at 6:20 PM
finance.yahoo.com logoKnight Therapeutics Announces Filling of Supplement to a New Drug Submission for NERLYNX® (neratinib) to Treat HER2-Positive Metastatic Breast Cancer
finance.yahoo.com - September 3 at 7:07 PM
finance.yahoo.com logoWhy Knight Therapeutics' (TSE:GUD) CEO Pay Matters
finance.yahoo.com - August 18 at 2:13 PM
Get Knight Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KHTRF and its competitors with MarketBeat's FREE daily newsletter.

This page (OTCMKTS:KHTRF) was last updated on 3/27/2023 by MarketBeat.com Staff